PyInvesting

Market research

12R.F 12R

F EUR Communication Services

Latest close

0.0358 —

As of 29 Oct 2026

Test a moving-average rule with historical data.

Market facts
Market cap
422K
P/E ratio
1.17
Analyst target
Not available
Dividend yield
Not available
Beta
-0.13

Community

Investor discussion

1 comment

Admin profile picture
Admin

5 years, 6 months ago

Recipharm AB (publ) is currently in a long term uptrend where the price is trading 28.8% above its 200 day moving average.

From a valuation standpoint, the stock is 99.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.1.

Recipharm AB (publ)'s total revenue rose by 33.4% to $3B since the same quarter in the previous year.

Its net income has dropped by 48.6% to $46M since the same quarter in the previous year.

Finally, its free cash flow grew by 297.7% to $200M since the same quarter in the previous year.

Based on the above factors, Recipharm AB (publ) gets an overall score of 4/5.